Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 12, 2019
2019 year-end update and 2020 outlook
Dec 03, 2019
Patent to 2034 granted in Europe for Neuren's NNZ-2591
Oct 31, 2019
Phase 3 trial of trofinetide in Rett syndrome commences
Oct 18, 2019
Neuren Corporate Presentation, October 2019
Oct 17, 2019
Appendix 4C - quarterly
Oct 16, 2019
FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
Oct 16, 2019
Pause in Trading
Oct 11, 2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
Sep 20, 2019
Neuren approaching key milestones in Q4 2019
Aug 28, 2019
Neuren advances pipeline for neurodevelopmental disorders
1
2
3
4
Next